Chemomab
Chemomab Therapeutics is a clinical-stage biotech developing nebokitug, a first-in-class monoclonal antibody neutralizing CCL24, for fibro-inflammatory diseases with high unmet need, primarily primary sclerosing cholangitis and systemic sclerosis. The pre-revenue company is seeking a partner to fund Phase 3 and commercialization.
- Company typePublic
- Founded2011
- HeadquartersTel Aviv, Israel
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Chemomab does
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company founded in 2011 in Tel Aviv, Israel, and listed on NASDAQ under ticker CMMB following a March 2021 reverse merger with Anchiano Therapeutics. The company is focused on discovering and developing therapeutics for fibro-inflammatory diseases with high unmet medical need, where uncontrolled healing processes drive a vicious cycle of chronic inflammation and fibrosis that replaces functional tissue with scar tissue. Chemomab's central scientific insight is that the soluble protein CCL24 is a key driver of this fibro-inflammatory cycle, and the company has built a pipeline around neutralizing CCL24.
The company's lead and only clinical asset is nebokitug (formerly CM-101), a first-in-class dual-activity monoclonal antibody designed to bind and neutralize CCL24. By blocking CCL24, nebokitug interrupts both the immune-cell recruitment/pro-fibrotic polarization pathway and the direct activation of tissue fibroblasts that enhances their transition into myofibroblasts. Chemomab has reported positive data from five clinical trials of nebokitug, including 15-week and 48-week data from the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), a rare and devastating fibrotic disease of the bile ducts with no approved therapy. The program has received FDA and EMA Orphan Drug Designations and FDA Fast Track Designation, and the FDA has aligned on a single pivotal Phase 3 trial as the registrational pathway. The company also holds an open U.S. IND for systemic sclerosis (scleroderma) and has secured composition-of-matter and methods patents in the US, Europe, Japan, China (through 2038), and Russia (through 2041).
Chemomab is pre-revenue, with no commercialized products. Its business model relies on a one-time license/partnership revenue stream, and the company is actively seeking strategic collaborations and licensing deals to fund the Phase 3 PSC trial and to commercialize nebokitug across the US, Europe, China, and Russia. A $10 million private placement in July 2024 from HBM Healthcare Investments, OrbiMed, and Sphera Biotech Master Fund extended the cash runway to early 2026. The company is small (11–50 employees), with a market capitalization of approximately $11.1M, and is led by co-founder, CEO, and CSO Adi Mor, PhD, with a board that includes senior pharmaceutical executives from Novo Nordisk, Alexion, Bristol-Myers Squibb, and Shire.
Chemomab firmographics
Firmographics- Name
- Chemomab
- Legal name
- Chemomab Therapeutics Ltd.
- Website
- https://chemomab.com
- Company type
- Public
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Chemomab Therapeutics is a clinical-stage biotech developing nebokitug, a first-in-class monoclonal antibody neutralizing CCL24, for fibro-inflammatory diseases with high unmet need, primarily primary sclerosing cholangitis and systemic sclerosis. The pre-revenue company is seeking a partner to fund Phase 3 and commercialization.
- Ownership category
- akta.pro rank
Chemomab industry classification
Industry- Product category
- Clinical-Stage Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)
Keywords
Where Chemomab is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Chemomab business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: As a clinical-stage biotechnology company, Chemomab does not yet have commercialized products. The company is developing nebokitug for fibro-inflammatory diseases with high unmet need and will seek to commercialize through partnerships or direct sales if regulatory approvals are obtained.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Chemomab product offering
Product offeringCore offering
Chemomab is a clinical-stage biotechnology company developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes the soluble protein CCL24 to treat fibro-inflammatory diseases. Its lead indication is primary sclerosing cholangitis (PSC), with additional development planned for systemic sclerosis. The company is preparing for Phase 3 trial initiation and intends to commercialize through strategic partnerships and licensing.
Product overview
Chemomab is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical need. The company's lead product candidate is nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes the soluble protein CCL24. Nebokitug operates on the company's Anti-CCL24 Therapeutic Platform and is being developed primarily for primary sclerosing cholangitis (PSC), with the Phase 2 SPRING trial completed and Phase 3 preparation underway. The company has reported positive results from five clinical trials of nebokitug, which has received FDA and EMA Orphan Drug designations and FDA Fast Track designation for PSC treatment.
Differentiator
Problem solved
Functional benefit
Brands
- Nebokitug: First-in-class dual activity monoclonal antibody that neutralizes CCL24, developed for the treatment of fibro-inflammatory diseases including primary sclerosing cholangitis (PSC) and systemic sclerosis. Formerly known as CM-101.
Products and services
- Nebokitug (CM-101) Nebokitug (formerly CM-101) is a first-in-class dual activity monoclonal antibody that binds to and neutralizes the soluble protein CCL24, designed to interrupt the fibro-inflammatory vicious cycle that promotes liver, skin, and lung fibrosis. It is being developed primarily for primary sclerosing cholangitis (PSC), with additional development for systemic sclerosis. The candidate has demonstrated disease-modifying potential and favorable safety profile in clinical trials, including sustained reductions in fibrosis and inflammation biomarkers over 48 weeks in the Phase 2 SPRING trial, and has received FDA and EMA Orphan Drug and FDA Fast Track designations.
Quantifiable outcome
- Sustained reductions in fibrosis and inflammation biomarkers over 48 weeks in Phase 2 SPRING trial
- +2 more outcomes
Companies that use Chemomab
Customer profileSegments2 records
Ideal customer profiles2 records
Chemomab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Chemomab partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights6 records
Chemomab competitors and assessment
Company assessmentDirect peers
- Intercept Pharmaceuticals: Intercept was the most advanced PSC drug developer historically (obeticholic acid in the AESOP/Phase 2 trials). Direct comparability: same lead indication (PSC), same liver fibrosis space, similar regulatory positioning via Orphan Drug pathway.
- Mirum Pharmaceuticals: Mirum focuses on rare liver diseases with approved bile-acid related therapies (Livmarli/Chenodal) and has active PSC interest. Comparable: rare/pediatric liver indications, similar Orphan Drug strategy, complementary commercial infrastructure in hepatology.
- Pliant Therapeutics: Clinical-stage biotech developing integrin-based therapeutics for fibro-inflammatory diseases including PSC and IPF. Comparable: fibro-inflammatory target portfolio, clinical stage, and orphan hepatology/pulmonary focus similar to Chemomab's fibrotic platform.
- Genfit: Genfit is a liver-focused biotech with elafibranor (Iqirvo) approved for PBC and a pipeline exploring fibrosis and PSC-adjacent indications. Comparable: liver disease specialty, fibro-inflammatory mechanism, Orphan pathway strategy.
Broad incumbents
- Madrigal Pharmaceuticals: Madrigal received the first FDA approval for MASH/NASH with resmetirom (Rezdiffra), establishing the liver fibrosis approved market. Comparable: liver fibrosis commercial pathway that Chemomab hopes to follow with nebokitug.
- Galapagos NV: Galapagos has clinical fibrosis programs in IPF and Systemic Sclerosis-ILD, including ziritaxestat historically. Comparable: fibro-inflammatory pipeline overlap in systemic sclerosis and pulmonary fibrosis.
- Boehringer Ingelheim: Boehringer markets nintedanib (Ofev) for SSc-ILD and IPF, the established anti-fibrotic incumbent. Comparable: SSc-ILD overlap with Chemomab's systemic sclerosis IND and broad antifibrotic franchise Chemomab's licensing deal would compete against.
- Bristol Myers Squibb: BMS is a major immunology/liver player with potential PSC interest and significant biologic expertise. Comparable: large pharma that could be a strategic acquirer/partner for Chemomab in licensing the PSC asset globally.
Emerging players
- Argenx: Commercial-stage immunology biotech with first-in-class FcRn antibody (efgartigimod) for autoimmune disease. Comparable: first-in-class monoclonal antibody platform for autoimmune/fibrotic disease with similar Orphan regulatory patterns.
- Terns Pharmaceuticals: Terns is a clinical-stage oral small-molecule biotech focused on liver disease and oncology, including adipocrinology and oncology. Comparable: liver-disease clinical-stage biotech profile, similar partnership-driven operating model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Chemomab social profiles
Digital presenceChemomab compliance and trust
Trust signalCompliance3 records
Chemomab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chemomab leadership team
Management profileNumber of profiles
Profiles8 records
Chemomab funding detail
Funding detailFunding overview
Funding rounds5 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chemomab M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chemomab
What does Chemomab do?
Chemomab is a clinical-stage biotechnology company developing nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes the soluble protein CCL24 to treat fibro-inflammatory diseases. Its lead indication is primary sclerosing cholangitis (PSC), with additional development planned for systemic sclerosis. The company is preparing for Phase 3 trial initiation and intends to commercialize through strategic partnerships and licensing.
Is Chemomab a public or private company?
Chemomab is a public company. It is classified as public and is currently operating.
When was Chemomab founded?
Chemomab was founded in 2011. It employs 11 to 50 people.
Where is Chemomab based?
Chemomab is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Chemomab make money?
One revenue line is on record: drug Development and Commercialization.
Who are Chemomab's main competitors?
Direct peers on record are Intercept Pharmaceuticals, Mirum Pharmaceuticals, Pliant Therapeutics and Genfit. Broad incumbents are Madrigal Pharmaceuticals, Galapagos NV, Boehringer Ingelheim and Bristol Myers Squibb. Emerging players are Argenx and Terns Pharmaceuticals.
Does Chemomab have an API?
No public API is recorded for Chemomab.
What industry is Chemomab in?
Chemomab's product category is Clinical-Stage Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAGAFAL, Formulation & Preclinical CMC Support (Nonclinical). Its NAICS code is 325414 and its SIC code is 2836.